

**Zoono Group Limited (ASX: ZNO)
ASX ANNOUNCEMENT**

22 April 2024

Extension of Rights Issue Closing Date

Zoono Group Limited (Company) (ASX: ZNO) advises that the closing date for the pro-rata non-renounceable rights issue of one (1) new Share for every two (2) existing Shares held by Eligible Shareholder on the Record Date at an issue price of \$0.027 per Share, to raise up to \$2.9M (before costs) (**Offer**) has been extended to Friday, 3rd May 2024 to allow additional time for Eligible Shareholder to take up their entitlements.

Eligible Shareholders (other than Directors and related parties of the Company) may subscribe for additional shares beyond their Entitlement on the basis that some existing Shareholders may fail to fully take up their Entitlement.

The revised timetable is as follows:

Announcement of Offer and Appendix 3B	12 December 2023
Lodgement of Cleansing Statement and Offer Document with ASX	5 April 2024
Ex date	9 April 2024
Record Date for determining Entitlements	10 April 2024
Offer Document despatched to Eligible Shareholders	15 April 2024
Last day to extend the Closing Date	30 April 2024
Closing Date* as at 5:00pm (AEDT)	3 May 2024
Shares quoted on a deferred settlement basis	6 May 2024
ASX notified of under subscriptions	10 May 2024
Issue date / Shares entered into Shareholders' security holdings	10 May 2024
Quotation of Securities issued under the Offer	13 May 2024

*Dates are indicative and subject to change. The Company reserves the right to amend any or all dates and times subject to the Corporations Act, the ASX Listing Rules and other applicable laws. The Directors may extend the Closing Date by giving at least three (3) Business Days' notice to ASX prior to the Closing Date. Accordingly, the date the Securities are expected to commence trading on ASX may vary.

Eligible Shareholders should consider the Offer Document in deciding whether to acquire securities under the rights issue and follow the instructions on the entitlement and acceptance form that accompanies the document.

This announcement has been authorised and approved for release to ASX by the Board of Zoono Group Limited.

For further information, please contact:

Zoono Group Limited

Paul Hyslop

Group MD

M: +64 21 659 977

E: paul.hyslop@zoono.com

Paul Ravlich

Group CFO

M: +64 21 075 9176

E: paul.ravlich@zoono.com

About Zoono

Zoono Group Limited is a global biotech company that develops, manufactures and distributes a suite of scientifically validated, long-lasting and environmentally friendly antimicrobial solutions. Zoono's mission is to improve health and well-being through innovative, safe, non-toxic and durable germ protection.

Zoono produces sprays, wipes and foams suited for skin care, surface sanitisers, and mould remediation treatments. The products are based on the 'ZOONO molecule', a unique antimicrobial molecule that bonds to any surface and kills pathogens including bacteria, viruses, algae, fungi and mould.

Zoono's products have received numerous regulatory approvals and the Company's technology claims are supported by independent testing conducted in laboratories worldwide. Zoono is headquartered in New Zealand and its products are available globally.

To learn more, please visit: www.zoono.com